Oruka Reports Positive Week 28 ORKA-001 Psoriasis Data
MENLO PARK, Calif. — September 23, 2026 Oruka Therapeutics announced positive Week 28 data from the ongoing EVERLAST-A Phase...
plaque psoriasis
Advertisement
Johnson & Johnson Wins EU Approval for ICOTYDE in Psoriasis
Beerse, Belgium, September 21, 2026 Johnson & Johnson has reached a major European regulatory milestone with the European Commission’s...
Can-Fite Advances Phase III Programs With FDA and EMA Status
RAMAT GAN, Israel, August 12, 2026 Can-Fite BioPharma Ltd. announced an update on the regulatory status of its two...
Alumis Advances Envudeucitinib With 54% PASI 100 Response
SOUTH SAN FRANCISCO, California, August 10, 2026 Alumis Inc. announced topline long-term results from the ongoing Phase 3 ONWARD3...
Philips Reports Strong Q2 2026 Growth and AI Innovation
Amsterdam, Netherlands, July 27, 2026 Royal Philips has reported solid second-quarter 2026 financial results, driven by 4% comparable sales...
Advertisements
InnoCare Phase III TYK2 Study Meets Psoriasis Endpoint
Beijing, July 27, 2026 InnoCare Pharma has announced that its novel TYK2 (Tyrosine Kinase 2) inhibitor fadeucravacitinib (ICP-488) successfully...
Takeda Reports Strong Phase 3 Zasocitinib Results
Osaka, Japan & Cambridge, Mass., July 16, 2026 Takeda announced new Phase 3 data demonstrating that its investigational oral...
Can-Fite Completes Phase 3 Psoriasis Trial Enrollment
RAMAT GAN, Israel, July 6, 2026 Can-Fite BioPharma announced the completion of enrollment of the first 247 patients in...
Junshi Biosciences Expands Roconkibart Through Fosun Alliance
Shanghai, China, July 1, 2026 Junshi Biosciences has entered into a landmark licensing collaboration with Fosun Wanbang Pharma Group,...
Arcutis Secures FDA Approval for ZORYVE in Children Aged 2+
WESTLAKE VILLAGE, Calif., June 29, 2026 Arcutis Biotherapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Advertisement
